Drew Pardoll (Chairman), M.D., Ph.D.
Dr. Pardoll serves as the Abeloff Professorship of Oncology, Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director of the Cancer Immunology Program at the Johns Hopkins School of Medicine. Over the past two decades, Dr. Pardoll has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of several immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes-based cancer vaccines. Dr. Pardoll is an author on over 200 peer-reviewed articles as well as more than 20 book chapters on T cell immunology and cancer vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell, and has served on the Scientific Advisory Boards for numerous academic and corporate institutions.
Thomas Gajewski, M.D., Ph.D.
Dr. Gajewski is the leader of the Immunology and Cancer program at the University of Chicago Comprehensive Cancer Center, Director of Melanoma Oncology, and a Professor in the Ben May Cancer Institute. His research interests include the role of the STING (Stimulator of Interferon Genes) pathway in immunity, the molecular and cellular regulation of T lymphocyte activation and differentiation, and the application of this information in immune-based cancer therapy. Dr. Gajewski has published more than 200 papers in peer-reviewed journals on basic aspects of T cell biology, anti-tumor immunity, and melanoma therapy. He was formerly President of the Society for Immunotherapy of Cancer, has served as an editor for Cancer Research and the Journal for Immunotherapy of Cancer and has received numerous awards and honors including the Burroughs Wellcome Fund Clinical Scientist Award for Translational Research and the American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy.
Nathanael Gray, Ph.D.
Dr. Gray is the Nancy-Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Dana Farber Cancer Institute. He leads the Dana Farber Program in Chemical Biology and manages a research laboratory. Previously, Dr. Gray was the Director of Biological Chemistry at the Novartis Institute for Genomics (GNF) in San Diego where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs including ceritinib, siponimod and ABL001. Dr. Gray received his Ph.D. in organic chemistry from Professor Peter Schultz at the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995.
Darren Higgins, Ph.D.
Dr. Higgins is a professor of Microbiology and Immunobiology at Harvard Medical School. His laboratory focuses on understanding fundamental host-pathogen interactions that lead to virulence, and the development of protective immunity to intracellular pathogens. He serves as an editorial board member and reviewer for several prominent journals (Cell, Nature, PLoS Pathogens) and has led projects on antigen discovery and vaccine development for the New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases, Boston Children’s Hospital, and the Dana Farber Cancer Center. Dr. Higgins is an author on over 50 peer-reviewed articles, is an inventor on several patents and has received numerous awards and honors. He co-founded and served on the Scientific Advisory Board of Genocea Biosciences Inc.
F. Stephen Hodi, M.D.
Dr. Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, the Sharon Crowley Martin Chair in Melanoma at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. Dr. Hodi is an internationally recognized leader in the development of immune therapy and melanoma therapeutics. He is known for the clinical development of immune checkpoint inhibitors, and his clinical investigation efforts have pioneered the use of immune checkpoint blockade and combinatorial approaches to treat cancer. He is an author on over 100 peer-reviewed articles including publications in the Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and the New England Journal of Medicine. He serves on the editorial board of several immunology and oncology journals and has received numerous awards and honors.
Frank McCormick, Ph.D., F.R.S., D.Sc.
Dr. McCormick is Professor of the UCSF Helen Diller Family Comprehensive Cancer Center and Department of Cellular and Molecular Pharmacology. He currently holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide. In addition, Dr. McCormick’s group led to the identification of a CDK4 kinase inhibitor. Dr. McCormick's current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies.
Dr. Mekalanos is the Adele H. Lehman Professor of Microbiology and Immunobiology at Harvard Medical School. He has served as Chair of the Microbiology and Molecular Genetics Department since 1996, and he is a member of the National Academy of Sciences and the American Academy of Microbiology. His research investigates multiple facets of bacterial pathogenesis, with an emphasis on exploring virulence gene regulation and host-pathogen interactions. Recent awards include the Drexel Medicine Prize in Infectious Disease and the Sanofi-Institut Pasteur Award for Biomedical Research.
Wiebe Olijve, Ph.D.
Dr. Olijve is an experienced research leader. He came out of retirement to serve as CEO and co-founder of BioNovion (now Aduro Biotech Europe), a company focused on the development of B-select antibodies for the treatment of serious diseases. Prior to BioNovion, he was vice president of the Research Biologics Council at Schering-Plough Research Institute (now Merck Research Laboratories). Previously, he served as vice president and site head of Schering-Plough Biopharma. Prior to Schering-Plough, he spent over 30 years in leadership positions at Organon Research pioneering new programs and initiating genomics and bioinformatics for target identification, contributing to research advancement in both the Netherlands and the United States. He has served as a professor of Applied Biology at Radboud University, Nijmegen in the Netherlands since 1990. Dr. Olijve is an author on numerous publications.
David H. Raulet, Ph.D.
Dr. Raulet is a tumor immunologist who holds the Esther and Wendy Schekman Chair in Basic Cancer Biology, and is a Professor of Immunology and Pathogenesis in the department of Molecular and Cell Biology at the University of California, Berkeley. His research primarily addresses the specificity and function of innate lymphocytes such as natural killer (NK) cells, and T cells. His efforts focus on mechanisms of tumor immune-surveillance and approaches for immunotherapy of cancer. Over a period of 33 years, he has played a significant role in defining inhibitory and activating receptors on NK cells and mechanisms of tumor recognition mediated by these receptors, and the roles of these receptors in tumor immune-surveillance. He is an author on over 200 peer-reviewed articles, has served on the editorial board for numerous immunology and oncology journals and has received numerous awards and honors.